Meeting
2018 ASCO Annual Meeting
Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients.
Authors
Tapan M. Kadia
The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX
Tapan M. Kadia , Jorge E. Cortes , Ahmad Ghorab , Farhad Ravandi , Elias Jabbour , Naval Guastad Daver , Yesid Alvarado , Maro Ohanian , Marina Konopleva , Hagop M. Kantarjian
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT02532231
Citation
J Clin Oncol 36, 2018 (suppl; abstr 7014)
DOI
10.1200/JCO.2018.36.15_suppl.7014
Abstract #
7014
Poster Bd #
74
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Pre-transplant molecular minimal residual disease (MMRD) is associated with inferior outcomes in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.
First Author: Muhammad Husnain
Poster
2017 ASCO Annual Meeting
Phase IB/II study of nivolumab with azacytidine (AZA) in patients (pts) with relapsed AML.
First Author: Naval Guastad Daver
Poster
2021 ASCO Annual Meeting
Molecular annotation of extramedullary acute myeloid leukemia to identify prevalence of targetable mutations.
First Author: Somedeb Ball
Poster
2018 ASCO Annual Meeting
Outcomes with inotuzumab ozogamicin (InO) in patients with Philadelphia chromosome–positive (Ph+) relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).
First Author: Wendy Stock